SEGLUROMET 500 mg/1

Segluromet 500 mg/1 combines ertugliflozin and metformin hydrochloride for managing type 2 diabetes. This oral medication supports blood sugar control as part of a broader treatment plan.

Segluromet 500 mg/1 is typically used to improve glycemic control in adults with type 2 diabetes. It works by combining two active ingredients: ertugliflozin, which helps the kidneys remove excess glucose, and metformin, which reduces glucose production in the liver. This combination is often part of a comprehensive diabetes management strategy that includes diet and exercise.

Common effects of Segluromet 500 mg/1 may include gastrointestinal discomfort, such as nausea or diarrhea, particularly when starting treatment. Some users may also experience urinary tract infections or low blood sugar levels, especially when combined with other diabetes medications. These effects vary and are not experienced by everyone.

Segluromet 500 mg/1 should be used with caution in individuals with kidney issues or those at risk of lactic acidosis. It is important to stay hydrated and monitor kidney function regularly. Always consult a healthcare provider before starting or adjusting any medication.

Segluromet 500 mg/1 may interact with certain medications, including diuretics, ACE inhibitors, and other diabetes treatments. Alcohol can increase the risk of lactic acidosis, so it should be avoided. Always inform your healthcare provider about all medications you are taking to avoid potential interactions.